Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma

NCT00187122 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2008-04-23

No results posted yet for this study

Summary

The main purpose of this study is to determine if it is feasible to administer an intensified, multi-agent chemotherapy regimen for children with stage III and IV non-Hodgkin lymphoma and to find out what the toxicities are.

Conditions

  • Lymphoblastic Lymphoma

Interventions

DRUG

Vincristine

See Detailed Description section for description of treatment plan.

PROCEDURE

Radiation Therapy

See Detailed Description section for description of treatment plan.

DRUG

Daunomycin

See Detailed Description section for description of treatment plan.

DRUG

L-Asparaginase

See Detailed Description section for description of treatment plan.

DRUG

Cytarabine

See Detailed Description section for description of treatment plan.

DRUG

Methotrexate

See Detailed Description section for description of treatment plan.

DRUG

Mercaptopurine

See Detailed Description section for description of treatment plan.

DRUG

Etoposide

See Detailed Description section for description of treatment plan.

DRUG

Cyclophosphamide

See Detailed Description section for description of treatment plan.

DRUG

Prednisone

See Detailed Description section for description of treatment plan.

DRUG

Dexamethasone

See Detailed Description section for description of treatment plan.

Sponsors & Collaborators

Principal Investigators

  • Raul C. Ribeiro, M.D. · St. Jude Children's Research Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1993-03-31
Primary Completion
2004-06-30
Completion
2004-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00187122 on ClinicalTrials.gov